CAR-T news - the latest biotech news from Labiotech.eu

Innovent and IASO Bio obtain approval for CAR-T multiple myeloma treatment

Jim Cornall — Tue, 04 Jul 2023 09:32:25 +0000

Innovent Biologics, Inc. and IASO Biotechnology have announced that China’s National Medical Products Administration (NMPA) has approved the New Drug Application (NDA) for FUCASO (Equecabtagene Autoleucel). FUCASO is the first fully-human BCMA-directed chimeric antigen receptor (CAR) T-cell therapy for adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least three prior […]

The post Innovent and IASO Bio obtain approval for CAR-T multiple myeloma treatment appeared first on Labiotech.eu.

© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Kelonia presents ‘compelling evidence’ for transformative multiple myeloma treatment

Jim Cornall — Fri, 19 May 2023 11:49:02 +0000

Kelonia Therapeutics, a biotech company working on in vivo gene delivery, has announced the results of preclinical research demonstrating that its in vivo Gene Placement System (iGPS) technology efficiently delivered CAR molecules specifically to T cells at therapeutic dose levels in both mice and non-human primates (NHPs). Kelonia’s iGPS platform enables CAR T cell therapy […]

The post Kelonia presents ‘compelling evidence’ for transformative multiple myeloma treatment appeared first on Labiotech.eu.

Five advancements in lupus research over the past year

Roohi Mariam Peter — Thu, 04 May 2023 11:56:51 +0000

A condition that affects around five million people worldwide, lupus has no proven cure. But various treatments for the disease have been around for more than a century, and lupus research has grown over the years. The first kind of therapy for the autoimmune disease – which occurs due to an overactive immune system that […]

The post Five advancements in lupus research over the past year appeared first on Labiotech.eu.

Immunotherapy in the fight against solid tumors

Willow Shah-Neville — Wed, 03 May 2023 14:09:08 +0000

Ever since William Coley first attempted to harness the immune system in 1891 to treat bone cancer, immunotherapy has been explored in the treatment of various different cancers – both solid and liquid – and has revolutionized and rejuvenated the field of oncology. However, despite certain immunotherapy treatments having shown very promising results, such as […]

The post Immunotherapy in the fight against solid tumors appeared first on Labiotech.eu.

Cabaletta Bio’s lupus drug cleared for trial

Jim Cornall — Tue, 02 May 2023 11:07:55 +0000

Cabaletta Bio, Inc., a U.S. clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation to CABA-201. Cabaletta Bio’s CABA-201 is a 4-1BB-containing fully human CD19-CAR T cell investigational therapy, designed […]

The post Cabaletta Bio’s lupus drug cleared for trial appeared first on Labiotech.eu.

10 immunotherapy companies making waves in 2023

Roohi Mariam Peter — Wed, 15 Mar 2023 15:00:00 +0000

Immunotherapy has been widely studied in cancer treatment research, ever since William Coley, who is regarded as the father of immunotherapy, first attempted to leverage the immune system for oncological therapy in 1891. Soon enough, the transformative power of cancer vaccines were observed where tumor-specific antigens triggered antitumor immune responses. Along with these technological advancements, […]

The post 10 immunotherapy companies making waves in 2023 appeared first on Labiotech.eu.

How the microbiome can predict cancer immunotherapy success

Jim Cornall — Tue, 14 Mar 2023 10:18:24 +0000

A new study shows antibiotic treatment prior to CAR-T cell therapy is connected to unfavorable treatment outcomes. An international team headed by Eran Elinav of the Cancer & Microbiome Division of the German Cancer Research Center (DKFZ), and led by Christoph Stein-Thoeringer, professor of Clinical Infectiology and Translational Microbiome Research at the Medical Faculty of […]

The post How the microbiome can predict cancer immunotherapy success appeared first on Labiotech.eu.

Peter MacCallum Cancer Centre and Cartherics to work on CAR-T cell therapy for ovarian cancer

Jim Cornall — Tue, 28 Feb 2023 11:09:36 +0000

Peter MacCallum Cancer Centre (Peter Mac) in Australia and Cartherics Pty Ltd have entered into a collaborative development program agreement (CDPA) to develop Cartherics’ proprietary autologous CAR-T cell therapy (CTH-004) for the treatment of ovarian cancer. The clinical trial to be conducted by Peter Mac will be the first time a CAR-T cell therapy product […]

The post Peter MacCallum Cancer Centre and Cartherics to work on CAR-T cell therapy for ovarian cancer appeared first on Labiotech.eu.

The benefits – and challenges – of in-house CAR T-cell therapy

Jim Cornall — Fri, 17 Feb 2023 11:52:48 +0000

The Sheba Medical Center in Israel has an advanced hemato-oncology center that offers in-house CAR T-cell therapy, the revolutionary immunotherapy that alters a patient’s white blood cells to kill cancer cells. By keeping the entire process at the hospital, and not sending the cells to an external lab, the quality of the T-cells are better […]

The post The benefits – and challenges – of in-house CAR T-cell therapy appeared first on Labiotech.eu.

Streamlining CAR-T cell therapy manufacturing: a platform approach

Alexander Burik — Tue, 07 Feb 2023 09:00:01 +0000

Chimeric antigen receptor-T cell (CAR-T) therapy is an exciting treatment modality for blood cancers that do not respond to standard treatment. But manufacturing these CAR-T therapies brings challenges. How can life science companies overcome them to minimize costs and improve patient access? In patients with cancer for whom chemotherapy proves unsuccessful, CAR-T therapy may provide […]

The post Streamlining CAR-T cell therapy manufacturing: a platform approach appeared first on Labiotech.eu.

Poolbeg expands POLB 001 into oncology

Jim Cornall — Tue, 17 Jan 2023 09:56:10 +0000

Poolbeg Pharma has announced the strategic expansion of POLB 001 into oncology. POLB 001 is a strain agnostic, small molecule immunomodulator being studied to address the unmet medical need for a treatment for severe influenza. While investigating the role of cytokine release syndrome (CRS) in severe influenza, Poolbeg discovered data specific to the overt immune […]

The post Poolbeg expands POLB 001 into oncology appeared first on Labiotech.eu.

Cartherics granted first patent in China

Jim Cornall — Mon, 09 Jan 2023 10:30:46 +0000

Cartherics Pty Ltd, a biotechnology company developing immune cell therapies for the treatment of cancer, has been granted a Chinese patent, “Genetically modified cells and uses thereof.” The patent provides a proprietary position for multiple development candidates in Cartherics’ pipeline. Specifically, it covers Cartherics’ chimeric antigen receptor (CAR) targeting tumor-associated glycoprotein-72 (TAG-72), along with T […]

The post Cartherics granted first patent in China appeared first on Labiotech.eu.

New biomarker for early prediction of response to CAR-T cell therapy

Jim Cornall — Mon, 09 Jan 2023 10:07:20 +0000

A MedUni Vienna research team in Austria has discovered a new highly potent biomarker for clinical response to CAR-T cell therapy, describing the prerequisites for optimal use of this novel therapy for lymphoma treatment. The current findings are an essential step forward towards optimizing this promising therapy. The results of the study were recently published […]

The post New biomarker for early prediction of response to CAR-T cell therapy appeared first on Labiotech.eu.

First CAR-T technology trial for patients with T-cell leukemia subtype authorized

Jim Cornall — Thu, 22 Dec 2022 10:06:02 +0000

The Spanish Agency of Medicines and Medical Products (AEMPS) has approved the CARxALL clinical trial led by the company OneChain Immunotherapeutics (OCI). It will be the world’s first trial with CAR-T technology for patients with a subtype of T-cell leukemia. The CARxALL trial will evaluate, for the first time, the CAR-T CD1a (OC-1) therapy. This […]

The post First CAR-T technology trial for patients with T-cell leukemia subtype authorized appeared first on Labiotech.eu.

Ebvallo approval ushers in off-the-shelf T-cell immunotherapies

Jonathan Smith — Tue, 20 Dec 2022 22:37:59 +0000

Patient-derived CAR-T immunotherapies have dominated the cancer immunotherapy space over the last decade. The EU approval of Atara Biotherapeutics’ Ebvallo marks the first immunotherapy based on T cells sourced from healthy donors. Since the approvals of Kymriah and Yescarta in 2017, CAR-T immunotherapies have changed the way we treat rare forms of blood cancer. In […]

The post Ebvallo approval ushers in off-the-shelf T-cell immunotherapies appeared first on Labiotech.eu.

Deciphering blood cancer complexity with multi-omics and patient-relevant disease models

External Contributor — Mon, 05 Dec 2022 09:00:03 +0000

The post Deciphering blood cancer complexity with multi-omics and patient-relevant disease models appeared first on Labiotech.eu.

Legend Biotech small cell lung cancer drug gets FDA ok for clinical development

Jim Cornall — Mon, 21 Nov 2022 16:19:33 +0000

Legend Biotech Corporation has announced that the U.S. Food and Drug Administration (FDA) has cleared Legend Biotech’s investigational new drug (IND) application to proceed with the clinical development of LB2102, an investigational, autologous chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of adult patients with extensive stage small cell lung cancer (SCLC). LB2102 is […]

The post Legend Biotech small cell lung cancer drug gets FDA ok for clinical development appeared first on Labiotech.eu.

SOTIO reveal potential treatment for adults with solid tumors at SITC meeting

Liza Laws — Thu, 10 Nov 2022 18:06:38 +0000

SOTIO Biotech has presented preclinical results of its BOXR T cell therapy platform and revealed it indicates a strong clinical path for its first transgene-expressing CAR-T cell as a potential treatment for solid tumors in adults with cancer. The results were presented at the Society for Immunotherapy of Cancer’s (SITC) 37th annual meeting taking place […]

The post SOTIO reveal potential treatment for adults with solid tumors at SITC meeting appeared first on Labiotech.eu.

Collaboration to develop CAR-T cell therapy for cutaneous T-cell lymphoma

Jim Cornall — Tue, 08 Nov 2022 08:19:05 +0000

The Peter MacCallum Cancer Centre (Peter Mac) and Cartherics Pty Ltd (Cartherics) have entered into a collaborative development program agreement (CDPA) to develop Cartherics’ proprietary autologous CAR-T cell therapy (CTH-001) for the treatment of cutaneous T-cell lymphoma (CTCL). “Patients with advanced stages of cutaneous T-cell lymphomas often have few treatment options left when their disease […]

The post Collaboration to develop CAR-T cell therapy for cutaneous T-cell lymphoma appeared first on Labiotech.eu.

Spanish research institution to use Elicera Therapeutics’ iTANK platform

Jim Cornall — Thu, 20 Oct 2022 13:53:19 +0000

Elicera Therapeutics AB has entered a material transfer agreement with the Josep Carreras Leukaemia Research Institute (JCLRI) in Spain for use of the iTANK platform in arming CAR T-cells for the treatment of Ewing Sarcoma. Sweden’s Elicera is a clinical stage cell and gene therapy company developing next generation immuno-oncological treatments based on enhanced oncolytic […]

The post Spanish research institution to use Elicera Therapeutics’ iTANK platform appeared first on Labiotech.eu.